

![]() |
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments |
|
Authors | ![]() | |
Published in | Pharmacogenetics and genomics. 2015, vol. 25, no. 5, p. 246-258 | |
Abstract | Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. | |
Identifiers | PMID: 25751397 | |
Full text | ||
Structures | ||
Research group | Médecine psychosomatique, neurosciences cliniques et mindfulness (690) | |
Citation (ISO format) | QUTEINEH, Lina et al. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. In: Pharmacogenetics and genomics, 2015, vol. 25, n° 5, p. 246-258. doi: 10.1097/FPC.0000000000000131 https://archive-ouverte.unige.ch/unige:78753 |